11 May 2023 – PLC commends ARS Pharmaceuticals for their recent favorable FDA Advisory Committee vote on the benefit-risk profile for neffy®. The Advisory Committee voted that neffy data supports a favorable benefit-risk assessment in adults and in children <18 years of age. PLC has supported ARS with Regulatory filings and clinical trial oversight since